Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if MBX is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
42 top institutions tracked
Last 13F trend: distributing (heavy)
Unlock crowding heatmapUnlock filer discoverySentiment: neutral
Last trade: sell 70 days ago
Red flags: 2
173 filers reported a long position in MBX for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | $367.2M | 6.7M | Unchanged |
| FMR LLC | $293.8M | 5.3M | +81.3% |
| WELLINGTON MANAGEMENT GROUP LLP | $274.8M | 5M | +55.9% |
| NEA Management Company, LLC | $199.5M | 3.6M | Unchanged |
| ORBIMED ADVISORS LLC | $189.3M | 3.4M | -5.7% |
| BlackRock, Inc. | $183.5M | 3.3M | +13% |
| Paradigm Biocapital Advisors LP | $138.4M | 2.5M | New |
| NVP Associates, LLC | $117.9M | 2.1M | Unchanged |
| Deep Track Capital, LP | $95.6M | 1.7M | -37.2% |
| Polar Capital Holdings Plc | $88.8M | 1.6M | -0.8% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.